Pharminent

Sanofi to Acquire Protein Sciences

NewsAcquisition adds recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio.Contributed Author: SanofiTopics: Pharma Mergers & Acquistions https://www.dddmag.com/news/2017/07/sanofi-acquire-protein-sciences

Filed under: Company

Alnylam Buckles Down On A Belt Of Rare Diseases

https://seekingalpha.com/article/4087017-alnylam-buckles-belt-rare-diseases

Filed under: Company

Pfizer To Lose Exclusivity Of Key Brands

https://seekingalpha.com/article/4082947-pfizer-lose-exclusivity-key-brands

Filed under: Company

J&J Innovation Reveals New Collaborations in NASH, Diabetes, and Rheumatoid Arthritis

NewsThese new deals will also help advance cutting-edge technologies, including 3-D printing to create customized health solutions.Contributed Author: J&J InnovationTopics: Biotech https://www.dddmag.com/news/2017/06/j-j-innovation-reveals-new-collaborations-nash-diabetes-and-rheumatoid-arthritis

Filed under: Company

Sanofi to invest further in biologics

PARIS (Reuters) – Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential.

http://www.reuters.com/article/us-sanofi-biologics-idUSKBN1951IV

Filed under: Company

Continuous Manufacturing: Novartis’ experiment in the future of drug production

Continuous manufacturing has long been touted as the future of drug production. Pharmafile approached Novartis for more details about its successes in the area, and the challenges, of developed the new process.
Why did Novartis decide to take the step to experiment in continuous manufacturing processes? 
read more http://www.pharmafile.com/news/514335/continuous-manufacturing-novartis-experiment-future-drug-production

Filed under: Company

AstraZeneca offloads more non-core assets

The British drugmaker has worked to trim its portfolio, selling off older drugs to help offset revenue declines from key products. http://www.biopharmadive.com/news/astrazeneca-offloads-more-non-core-assets/443315/

Filed under: Company

Pfizer taps Sangamo for hemophilia gene therapy

The deal validates Sangamo’s gene therapy technology and provides Pfizer with another gene therapy in the hemophilia space.  http://www.biopharmadive.com/news/pfizer-sangamo-hemophilia-gene-therapy/442527/

Filed under: Company

Novartis exercises option with Conatus for NASH treatment

Novartis has exercised its option with ConatusPharmaceuticals for an exclusive license for the worldwide development and commercialization of emricasan, a potential treatment for non-alcoholic steatohepatitis (NASH). http://drugdiscovery.pharmaceutical-business-review.com/news/novartis-exercises-option-to-develop-conatus-emricasan-to-treat-nash-050517-5805546

Filed under: Company

Cambridge’s bluebird bio licenses delivery tech to Novartis, GSK

http://www.bizjournals.com/boston/news/2017/05/02/cambridges-bluebird-bio-licenses-delivery-tech-to.html

Filed under: Company

Novartis looks earlier as biotech gets too expensive

The Swiss pharma is having trouble finding assets it likes to flesh out its pipeline as biotech valuations grow and its own earnings stay flat.  http://www.biopharmadive.com/news/novartis-looks-earlier-as-biotech-gets-too-expensive/441204/

Filed under: Company

Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration

DUBLIN, April 18, 2017 /PRNewswire/ — Allergan, a leading global biopharmaceutical company, announced today that it has entered into a clinical trial agreement with Novartis to conduct a Phase 2b study, using Allergan’s cenicriviroc (CVC) and Novartis’ lead FXR agonist for the treatment o… http://www.prnewswire.com/news-releases/allergan-expands-leading-research–development-nash-program-with-novartis-clinical-collaboration-300440168.html

Filed under: Company

Novartis Aims to Turn Around Its Surgical Business in 2017

http://marketrealist.com/2017/03/novartis-aims-turnaround-surgical-business-2017/

Filed under: Company

Sanofi to sell OTC products to Ipsen

Sanofi is selling certain European rights to five consumer healthcare products to fellow French drugmaker Ipsen, in a move that will help progress its planned asset swap deal with Boehringer Ingelheim. http://www.pharmatimes.com/news/sanofi_to_sell_otc_products_to_ipsen_1186494

Filed under: Company

Novartis reviewing options for Alcon, including possible spin-off

The Swiss pharma’s eye-care unit has struggled, spurring the review. At the same time, generic competition to Gleevec has put pressure on Novartis’ growth products.  http://www.biopharmadive.com/news/novartis-alcon-options-ipo-earnings-q4/434743/

Filed under: Company

AbbVie Unveils 4 Global R&D Collaborations Focused on Advancing Next-Gen Science

With more than 50 compounds in clinical development, AbbVie’s pipeline spans significant areas of medical need including oncology, immunology, neuroscience and virology. http://www.dddmag.com/news/2017/01/abbvie-unveils-4-global-r-d-collaborations-focused-advancing-next-gen-science

Filed under: Company

Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca

[Business Wire] – Pfizer Inc. today announced that it has completed the acquisition of the development and commercialization rights to AstraZeneca’s late-stage small molecule anti-infective business, primarily outside the United States. http://finance.yahoo.com/news/pfizer-completes-acquisition-small-molecule-070500358.html

Filed under: Company

Novartis to acquire Ziarco to expand dermatology portfolio

Novartis has agreed to acquire Ziarco Group, a privately held firm engaged in the development of novel treatments in dermatology. http://drugdiscovery.pharmaceutical-business-review.com/news/novartis-to-acquire-ziarco-to-expand-dermatology-portfolio-191216-5700215

Filed under: Company

Pfizer employs artificial intelligence for drug discovery

Pfizer has signed a deal with IBM Watson Health for use of its cognitive computing capabilities in the search for new cancer medicines. http://www.pharmatimes.com/news/pfizer_employs_artificial_intelligence_for_drug_discovery_1179712

Filed under: Company

Shire to Establish Rare Disease Innovation Hub in Cambridge, Mass.

LEXINGTON, Massachusetts, November 22, 2016 /PRNewswire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that it will expand its operations in Cambridge, Massachusetts, establishing a rare disease innovation hub and increasing its footprint in the heart of Kendall Square. Shire… http://www.prnewswire.com/news-releases/shire-to-establish-rare-disease-innovation-hub-in-cambridge-mass-602419365.html

Filed under: Company

Categories